New York – Pfizer, Roche Group, and Merck & Co., Inc. topped the list of the world’s most valuable biopharmaceutical brands in a new study released by consulting firm InterbrandHealth, a unit of Interbrand.
Best Pharma Brands, the consulting group’s inaugural “top 10” biopharma report, was based on global research data and feedback from healthcare professionals.
The analysis focused on the prescription portion of total revenue, excluding other revenue sources, such as consumer health, over-the-counter products, medical device sales, diagnostics, and animal health.
It also examined industry trends on topics such as the impact of corporate brand in an adoption decision, mergers and acquisitions, and corporate citizenship, according to InterbrandHealth.
The top 10 companies, representing approximately $129 billion in “brand” value, were ranked as follows:
- Pfizer ($19.985 billion)
- Roche Group ($15.479 billion)
- Merck & Co., Inc./MSD ($13.880 billion)
- Janssen, part of Johnson & Johnson ($13.866 billion)
- Novartis ($13.496 billion)
- Amgen ($13.461 billion)
- Gilead Sciences ($13.361 billion)
- Novo Nordisk ($10.206 billion)
- AstraZeneca ($8.123 billion)
- GSK ($6.778 billion)
To be considered, the companies were required to have a global presence, generate revenue from the sale of prescription medicines, report the ratio of revenues generated from sales of prescription medicines, possess a strong pipeline of potential future prescription medicines, have awareness among healthcare professionals, and serve as the primary external-facing manufacturer brand.
“Biopharma is at a pivotal moment, and the time for change is now,” Jane Parker, InterbrandHealth’s CEO, said in a press statement, adding that the ranked companies are growing their businesses, fueling innovation, and developing meaningful solutions for patients on a global scale.
Citing a desire in the healthcare community for solutions that go “beyond the pill,” biopharma companies are adapting their business models, increasing transparency, exploring nontraditional solutions in areas like digital therapies, and ramping up their corporate citizenship activities, according to InterbrandHealth.
“The biopharma industry has relied on blockbuster drugs for a long time, but healthcare is changing, and what physicians need has changed,” Dr. Ronnie Hershman, CEO of HealthEffect, LLC, said in the statement. “Biopharma companies need to shift and think about what else they can offer.” Hershman, a cardiologist, is affiliated with NYU Langone Long Island Cardiac Care.
Interbrand, established in 1974, has 29 offices in 22 countries. The company publishes an annual Best Global Brands report and operates brandchannel, a branding website. In addition to InterbrandHealth, the company has divisions focusing on retail in North America, Europe and Asia. It is a division of the Omnicom Group, Inc. network of marketing communications companies.
(Sources: Interbrand, InterbrandHealth, Omnicom Group, Inc., Business Wire)
Filed Under: Drug Discovery